BiotechTube
PathoQuest

PathoQuest

Paris, France· Est.
pathoquest.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20.5M

Overview

PathoQuest is a specialized CRO offering a disruptive, NGS-based approach to biologics quality control, replacing traditional in vivo and in vitro biosafety tests. Its validated iDTECT® platform provides faster, more comprehensive, and animal-free (3Rs) testing for viral adventitious agents and genetic characterization across multiple modalities, including cell therapies, viral vectors, and vaccines. The company has established a strong track record with numerous industry partners and is positioned at the forefront of modernizing biopharmaceutical quality assurance.

Diagnostics

Technology Platform

iDTECT® platform: GMP-validated Next-Generation Sequencing (NGS) assays for unbiased, broad-spectrum viral safety testing (adventitious agent detection) and genetic characterization of biopharmaceuticals.

Funding History

2
Total raised:$20.5M
Series B$12M
Series A$8.5M

Opportunities

The rapid growth of advanced therapies (cell/gene/viral vectors) creates urgent demand for faster, more comprehensive biosafety testing that traditional methods cannot meet.
Increasing regulatory acceptance of NGS and the industry-wide commitment to the 3Rs (replacing animal testing) provide a strong tailwind for platform adoption.
Expansion into new applications like cultivated meat and deeper partnerships with CDMOs represent significant new market avenues.

Risk Factors

Regulatory risk persists, as global health authorities must fully accept NGS as a primary release test, which is an evolving landscape.
Competition from larger CROs or diagnostic companies developing similar NGS services could intensify.
The business is also exposed to cyclical downturns in biopharma R&D funding, which could reduce client spending on quality control services.

Competitive Landscape

PathoQuest competes with traditional biosafety testing services offered by large CROs (e.g., Charles River Labs, Eurofins, Lonza) that use in vitro and in vivo methods. Its direct competitors are few but growing, including other specialized labs developing NGS-based microbial detection services. Its key competitive advantages are its first-mover status, GMP-validated iDTECT® platform, strong industry partnerships, and proven track record in supporting regulatory filings for advanced therapies.

More companies in Diagnostics & Precision Medicine →More companies in France →